Tag: Lou Gehrig’s

Experimental ALS drug wins EU orphan status

by Selina McKee | Aug 9, 2016 | News | 0

European regulators have assigned orphan drug status to an experimental therapy for Amyotrophic Lateral Sclerosis called masitinib, indicating that it has the potential to offer a significant benefit over existing treatment options.

FDA to review Mitsubishi’s ALS drug

by Selina McKee | Jun 22, 2016 | News | 0

US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.